WADA - WADA Technical Document – ISL TD2027EQAS

WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 1/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 WADA External Quality Assessment Scheme 1.0 Introduction and Scope This Technical Document (TD), which constitutes an integral part of the International Standard for Laboratories (ISL [1]), provides a description of the WADA External Quality Assessment Scheme (EQAS), including the scheme’s objectives ; types, number, and composition of EQAS samples; as well as Laboratory requirements for the analysis of EQAS samples and reporting of EQAS results.

The WADA EQAS is designed to: a) Continually monitor the proficiency of Laboratories (i.e., WADA-accredited Laboratories), including in preparation for and while performing Analytical Testing for Major Events [1]. b) Assess Laboratory routine analytical capacity and performance, reporting turnaround times and overall compliance with WADA Laboratory mandatory normative standards, i.e., the ISL [1], ISL TDs, and ISL Technical Letters (TLs), as well as other, non-analytical performance criteria. c) Improve test result uniformity between Laboratories. d) Assess Candidate laboratory and Probationary laboratory progress in preparation for WADA accreditation. e) Assess Laboratory and ABP Laboratory proficiency in the analysis of the Markers of the Hematological Module of the Athlete Biological Passport (ABP). f) Assess Candidate ABP laboratory progress in preparation for WADA approval. g) Provide a communication platform between WADA and Laboratories for sharing of knowledge and for continuous improvement of Analytical Testing Procedures (ATPs). 1.1 Compliance of WADA EQAS with ISO/IEC 17043 Standard

f) Assess Candidate ABP laboratory progress in preparation for WADA approval. g) Provide a communication platform between WADA and Laboratories for sharing of knowledge and for continuous improvement of Analytical Testing Procedures (ATPs). 1.1 Compliance of WADA EQAS with ISO/IEC 17043 Standard WADA is committed to conduct its EQAS to the highest standard and to ensure that it meets the goals and needs of its stakeholders, including the EQAS Participants. WADA EQAS meets the requirements of the ISO/IEC 17043 standard (Conformity Assessment - General Requirements for the Competence of Proficiency Testing Providers [2]) 1. The WADA EQAS Management System ( MS) and related EQAS activities are regularly audited by independent experts to continuously evaluate their conformity with the requirements of this standard.

1 All the elements of WADA’s EQAS MS underwent a thorough process of development, implementation, improvement and evaluation over a period of more than two (2) years, which included several Internal Audits and a further assessment by independent external auditors.WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 2/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 2.0 Types of EQAS Samples 2.1 Blind EQAS Samples a) Blind EQAS samples may be received by Laboratories, Candidate laboratories [as part of their Pre-Probationary Test (PPT)], and Probationary laboratories [during the probationary phase, and as part of their Final Accreditation Test (FAT)]. b) The blind EQAS Participant will be aware that the sample is an EQAS sample since it is

Pre-Probationary Test (PPT)], and Probationary laboratories [during the probationary phase, and as part of their Final Accreditation Test (FAT)]. b) The blind EQAS Participant will be aware that the sample is an EQAS sample since it is delivered by WADA’s EQAS Sample Provider 2. However, the Participant will not know the content of the EQAS samples. 2.2 Double-Blind EQAS Samples a) Double-blind EQAS samples are delivered to the Laboratories by Testing Authorities (TAs) or Delegated Third Parties (DTPs) and is indistinguishable from routine Samples. Therefore, the Laboratories will not be aware that the sample is an EQAS sample. b) For receiving doubleblind EQAS sample(s), the Laboratory shall be operational for the analysis of Samples, i.e., the Laboratory shall not be under Suspension nor subject to an Analytical Testing Restriction (ATR) affecting the application of ATPs or the analysis of substances that are within the scope of the double-blind EQAS exercise. 2.3 Educational EQAS Samples a) Educational EQAS samples may be received by Laboratories and Probationary laboratories. b) Educational EQAS samples may be provided as open (in which case the content of the EQAS sample is known to the Participants before reception), blind or double-blind samples.

1. When an educational EQAS sample is sent as an open or a blind sample, the Participants may vary according to the specific purposes of the EQAS round (e.g., for evaluation of Laboratory performance of nonmandatory Analytical Methods and for analysis of nonmandatory matrices). ii. If an educational EQAS sample is sent as a doubleblind sample, the Participants will not include Probationary laboratories. This approach is used for educational purposes or for data gathering.

2 WADA subcontracts the preparation, characterization and distribution of EQAS samples to an external EQAS Sample Provider(s), which

1. If an educational EQAS sample is sent as a doubleblind sample, the Participants will not include Probationary laboratories. This approach is used for educational purposes or for data gathering.

2 WADA subcontracts the preparation, characterization and distribution of EQAS samples to an external EQAS Sample Provider(s), which shall maintain an ISO/IEC 17025 [3] accreditation (and/or other relevant ISO accreditation, if applicable) from an Accreditation Body (AB) that is a full member of the Global Accreditation Cooperation Inc. and a signatory to the Mutual Recognition Arrangement (MRA) of the Global Accreditation Cooperation Inc. or, if not, it shall be full member of one of the approved and recognized Regional Cooperation Bodies, i.e., African Accreditation Cooperation (AFRAC), Asia Pacific Accreditation Cooperation Inc. (APAC), Arab Accreditation Cooperation (ARAC), European co -operation for Accreditation (EA), Inter American Accreditation Cooperation (IAAC), or Southern African Development Community Cooperation in Accreditation (SADCA) . In the absence of accreditation to a relevant ISO standard, the external EQAS Sample Provider(s) will be required to maintain an applicable recognized accreditation or certification(s), as determined by WADA.WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 3/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 c) As part of the educational EQAS, WADA may provide Participants with samples to be used as Quality Control (QC) samples for a prompt extension of existing or implementation of new ATPs. d) WADA may require the successful participation in an educational EQAS for WADA-specific

c) As part of the educational EQAS, WADA may provide Participants with samples to be used as Quality Control (QC) samples for a prompt extension of existing or implementation of new ATPs. d) WADA may require the successful participation in an educational EQAS for WADA-specific ATPs for Laboratories to seek an extension of the Laboratory’s Scope of ISO/IEC 17025 [3] Accreditation (refer to ISL [1] and the ISL TD ATP [4]) before the application of such ATP to the routine analysis of Samples. 3.0 EQAS Sample Number and Composition 3.1 Number of EQAS Samples The actual composition and number of EQAS samples supplied to different Participants may vary; however, within any calendar year, all L aboratories participating in the EQAS are expected to have analyzed a minimum total number of EQAS samples, as defined below. 3.1.1 Distribution of EQAS Samples 3.1.1.1 EQAS for Laboratories and Probationary laboratories WADA regularly distributes through its subcontracted EQAS Sample Provider(s) urine, blood and Dried Blood Spots (DBS) EQAS samples (including blind, double-blind and educational EQAS samples) to Laboratories and, where applicable, to Probationary laboratories. Each year, the EQAS shall consist, at least, of: a) Ten (10) blind EQAS samples, distributed over at least two (2) rounds (e.g., two (2) rounds of five (5) EQAS samples per round). b) Six (6) double-blind EQAS samples, distributed over at least two (2) rounds. Of the above sixteen (16) annual blindand double-blind EQAS samples:

1. At least three (3) EQAS samples will contain Threshold Substances , requiring the application of a Quantitative Procedure for confirmation. ii. At least three (3) EQAS samples will be DBS EQAS samples 3. c) At least one (1) educational EQAS exercise.

requiring the application of a Quantitative Procedure for confirmation. ii. At least three (3) EQAS samples will be DBS EQAS samples 3. c) At least one (1) educational EQAS exercise.

3 For Laboratories lacking validated ATPs for the analysis of DBS Samples, the corresponding number of EQAS samples will be replaced with EQAS samples prepared in urine or blood matrices.WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 4/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 3.1.1.2 EQAS for Analysis of the Markers of the Hematological Module of the ABP Laboratories and ABP Laboratories also participate in the EQAS for the Hematological Module of the ABP on a regular basis. WADA subcontracts this blood ABP EQAS program to an external Proficiency Testing Provider which is either ISO/IEC 17043accredited or follows the requirements of the ISO/IEC 17043 standard [2]. WADA also distributes blood ABP EQAS samples to Probationary laboratories wishing to become ABP approved before obtaining full WADA accreditation or aiming at implementing the Test Method upon obtaining WADA accreditation, and to Candidate ABP laboratories (see ISL [1]). 3.1.2 Additional (ad hoc) EQAS In addition to the blind, double-blind and educational EQAS, WADA also distributes EQAS samples to Candidate laboratories, Probationary laboratories and Laboratories on an ad hoc basis, including: a) Accreditation Tests (see ISL [1])

1. Blind EQAS samples for PPT of Candidate laboratories.

In addition to the blind, double-blind and educational EQAS, WADA also distributes EQAS samples to Candidate laboratories, Probationary laboratories and Laboratories on an ad hoc basis, including: a) Accreditation Tests (see ISL [1])

1. Blind EQAS samples for PPT of Candidate laboratories. ii. Blind EQAS samples for FAT of Probationary laboratories. iii. Blind EQAS samples for Laboratories seeking accreditation of a new physical location (“satellite facility”) in preparation for provision of Analytical Testing services

during Major Events. b) WADA Monitoring Activities As part of its monitoring of Laboratories and Probationary laboratories, and with the main purpose of assisting in their continuous improvement of performance, WADA may distribute additional EQAS samples to Laboratories and Probationary laboratories according, but not limited to, the following criteria (or other valid reasons, as determined by WADA):

1. To monitor the effectiveness of corrective action implementation after questionable or unsatisfactory performance in the WADA EQAS or in routine Analytical Testing. ii. As part of WADA Laboratory and Probationary laboratory assessments (see ISL [1] and ISL TD PERF [5]). iii. When intelligence information is received by WADA indicating suspect Laboratory performance.WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 5/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 iv. Distribution of blind or double-blind EQAS samples to Laboratories in preparation for or while performing Analytical Testing during Major Events (see ISL [1]) 4.

1. To assess Laboratory competence in applying a specific ATP, which is not part of

1. Distribution of blind or double-blind EQAS samples to Laboratories in preparation for or while performing Analytical Testing during Major Events (see ISL [1]) 4.
2. To assess Laboratory competence in applying a specific ATP, which is not part of the Laboratory’s routine Analytical Testing menu, when there are an insufficient number of routine Samples received for analysis. vi. To monitor progress of Probationary laboratories during WADA accreditation process. 3.2 Composition of EQAS Samples EQAS samples may or may not contain Analyte(s) of Prohibited Substance(s) and/or Prohibited

Method(s). [Comment to Article 3.2: For urine EQAS samples, in addition to analyzing for the presence of Analytes of Prohibited Substances and/or Prohibited Methods, the EQAS Participants shall quantify the Markers of the urinary steroid profile and measure the specific gravity (SG) of all EQAS samples, unless otherwise determined by WADA.] WADA will define the evaluation objectives and composition of each EQAS sample in an EQAS Plan. For Participants’ EQAS performance evaluation purposes ( see ISL TD PERF [5]), only the target Analyte(s) defined in the EQAS Plan will be considered. Any other Analyte(s) will only be considered for educational purposes. [Comment to Article 3.2: When an EQAS sample contains low levels of Analyte(s) of Prohibited Substance(s) and/or Prohibited Method(s), which are not detected during the EQAS sample characterization or are detected at trace levels prior to shipment to Participants, the detection and reporting of such unintended Analyte(s), which do not constitute an objective of the EQAS round, will not be considered for the purpose of EQAS performance evaluation]. 3.2.1 Blank EQAS Samples Blank EQAS samples do not contain Analyte(s) of Prohibited Substance(s) or Prohibited Method(s). 3.2.2 Adulterated EQAS Samples Adulterated EQAS samples are those samples that have been deliberately adulterated

3.2.1 Blank EQAS Samples Blank EQAS samples do not contain Analyte(s) of Prohibited Substance(s) or Prohibited Method(s). 3.2.2 Adulterated EQAS Samples Adulterated EQAS samples are those samples that have been deliberately adulterated (for example, but not limited to, by the addition of non-prohibited substances that share common Metabolite(s) with Prohibited Substances ) to assess adequate ATP coverage and results interpretation.

4 The distribution of double-blind EQAS samples during a Major Event may be done at WADA’s discretion and in collaboration with the Major Event Organization (MEO) (or DTP delegated to undertake Doping Control responsibilities for the Major Event), or upon request and at the expense of the MEO (or DTP).WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 6/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 3.2.3 EQAS Samples Containing Analyte(s) of Prohibited Substance(s) and/or Prohibited Method(s) a) EQAS samples may be spiked with Analyte (s) of Prohibited Substance(s) and/or Prohibited Method(s) but would be preferably prepared from controlled administration studies in humans. b) The EQAS sample composition shall reflect as closely as possible the Analyte pattern typically observed in routine Samples, at concentrations relevant for EQAS purposes. Therefore, the EQAS sample may contain the parent Prohibited Substance and/or its Metabolite(s) and/or its Marker(s) and/or its degradation products.

typically observed in routine Samples, at concentrations relevant for EQAS purposes. Therefore, the EQAS sample may contain the parent Prohibited Substance and/or its Metabolite(s) and/or its Marker(s) and/or its degradation products. The concentration(s) of selected Analyte (s) in EQAS samples are those that may be encountered in urine, blood (serum, plasma) or capillary blood (if data is not available for capillary blood, the concentration in venous blood may be considered) after Use of Prohibited Substances or Prohibited Methods. An EQAS sample may contain more than one Prohibited Substance and/or Prohibited Method. It may also contain multiple Analytes of a single Prohibited Substance and/or Prohibited Method, which would represent the presence of a single Prohibited Substance or the Use of a single Prohibited Method. [Comment to Article 3.2.3: Double-blind EQAS samples should be representative of routine Samples. Therefore, to the extent possible (in consideration, for example, of technical or ethical constraints, availability of the pharmaceutical grade substance, etc.), double -blind EQAS samples containing Prohibited Substances or Prohibited Methods should be prepared from controlled drug administration studies performed in human subjects (who are not Athletes), which shall be conducted in accordance with the Helsinki Declaration and any applicable national standards as they relate to the involvement of human subjects in research, including the obtaining of voluntary informed consent. However, if a drug administration study is not possible, then the double-blind EQAS sample(s) may be prepared by spiking expected target Analyte(s) in the sample matrix in consideration of the representative metabolic profile(s).] 4.0 Preparation and Characterization of EQAS Samples To ensure the highest quality of the EQAS samples and their suitability for evaluation of Participants’ performance, the EQAS samples are distributed to the Participants after preparation and characterization (for homogeneity and stability) according to established WADA protocols and ISO/IEC 17043 standard requirements [2]. WADA, as the Proficiency Testing Provider, maintains oversight of all externally provided

performance, the EQAS samples are distributed to the Participants after preparation and characterization (for homogeneity and stability) according to established WADA protocols and ISO/IEC 17043 standard requirements [2]. WADA, as the Proficiency Testing Provider, maintains oversight of all externally provided services for the EQAS, including the EQAS sample production, analysis, characterization, coding, storage, distribution and disposal by the EQAS Sample Provider. It is mandatory that the EQAS samples are characterized by ATPs commonly utilized in Laboratories in order to determine that the EQAS samples are acceptable. In cases where the external EQAS Sample Provider does not have the analytical capacity to perform such analysis, it may subcontract the analysis to another laboratory (including the possibility of using a Laboratory) for this service only if explicitly approved by WADA.WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 7/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 4.1 Suitability of Concentrations Once the EQAS sample is prepared, an analysis using a validated Quantitative Procedure is carried out by the external EQAS Sample Provider to determine the concentration(s) of the target Analyte(s) (unless a Qualitative Procedure, e.g., gel electrophoretic Test Methods for Erythropoiesis Receptor Agonists (ERAs), is considered sufficient to ensure the suitability of the EQAS sample, as determined by WADA ). The Analyte (s)’ concentrations in EQAS samples should meet the suitability criteria, established in WADA ’s procedures, for evaluation of Participants’ results in the EQAS (see ISL TD PERF [5]). 4.2 Homogeneity and Stability Testing of EQAS Samples

should meet the suitability criteria, established in WADA ’s procedures, for evaluation of Participants’ results in the EQAS (see ISL TD PERF [5]). 4.2 Homogeneity and Stability Testing of EQAS Samples The distribution of homogeneous and stable EQAS samples to the Participants is essential to ensure that their performance is correctly and fairly evaluated by inter -Laboratory comparison of their EQAS results. WADA has protocols and criteria for homogeneity and stability assessment of EQAS samples prepared according to the requirements of the international standards ISO/IEC 17043 [2] and ISO 13528 [6], which the external EQAS Sample Provider is required to follow to confirm that the criteria are met. The homogeneity and stability reports resulting from the analyses performed by the external EQAS Sample Provider are reviewed by WADA before the EQAS samples are shipped to the Participants in an EQAS round. 5.0 Analytical Testing Procedures Used in the EQAS a) All procedures associated with the Analytical Testing of the EQAS samples by the Participants are to be conducted as done for routine Samples, unless otherwise specified by WADA. b) No effort shall be made to modify instrument or method performance (e.g., specific changes that are not applicable to routine Samples, nonconforming to relevant Standard Operating Procedures (SOPs), or without proper validation) prior to analyzing the EQAS samples. c) Only validated, Fit-for-Purpose ATPs described in the Participant’s SOPs are to be employed in the analysis of EQAS samples ( i.e., using the Initial Testing Procedures (ITPs) and Confirmation Procedures (CPs) applied in routine Analytical Testing), unless otherwise specified by WADA. d) Any deviation from the requirements set above may increase the risk of invalid performance evaluation in an EQAS round (for EQAS results evaluation, see ISL TD PERF [5]).WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group

Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 8/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 6.0 Reporting EQAS Results 6.1 Reporting Blind EQAS Results a) Prior to the blind EQAS samples shipment, an EQAS Cover Letter is sent to the Participants, which provides all the relevant instructions on the analysis and reporting of EQAS results. The Participant shall report the EQAS results of blind EQAS samples to WADA under the same criteria as specified for routine Samples; however, the reporting is conducted in the ADAMS EQAS module, which is specially designed for only reporting EQAS results, unless otherwise notified by WADA. For some blind EQAS samples, the reporting of additional details [e.g., Limits of Detection (LODs), Limits of Identification (LOIs), Limits of Quantification (LOQs), Measurement Uncertainty (MU) estimations, estimated concentrations of Non -Threshold Substances with Minimum Reporting Levels (MRL), etc.] may be requested in the Cover Letter. The instructions for reporting this additional information (e.g., in designated result sheets) are also provided in the EQAS Cover Letter. b) The results of the blind EQAS samples shall be submitted to WADA on or before the specified reporting date, unless an extension is granted by WADA . A Laboratory failure to report blind EQAS results by the established deadline, without prior approval by WADA or on unjustified grounds, as determined by WADA, may result in the assignment of points to the Laboratory in accordance with the Points Scale Table (see ISL TD PERF [5]). c) Collusion between Participants regarding any aspect of the analysis of blind EQAS samples

grounds, as determined by WADA, may result in the assignment of points to the Laboratory in accordance with the Points Scale Table (see ISL TD PERF [5]). c) Collusion between Participants regarding any aspect of the analysis of blind EQAS samples (including the content of substances present in or absent from blind EQAS samples, quantitative results obtained, etc.) prior to the submission of EQAS results by all Participants to WADA is not allowed. Any such contact/communication between the Participants in the EQAS will be considered a violation of the ISL Code of Ethics [1] and an attempt to circumvent the quality assessment and will subject the Participants involved to Disciplinary Procedures, which may lead to Suspension or Revocation of WADA accreditation. This prohibition also applies to Participants ’ requests for second opinions, which shall not be requested for blind EQAS samples. 6.2 Reporting Double-Blind EQAS Results a) For double-blind EQAS samples, which are indistinguishable from routine Samples, the EQAS results are reported in ADAMS in the same way as routine test results. Consultation between Laboratories before reporting such EQAS results to WADA may occur. However, such consultation shall not involve identifying the Sample as a WADA double-blind EQAS sample (in cases when, for any reason, a Laboratory identifies the EQAS nature of the Sample). Laboratories shall request second opinions for double-blind EQAS samples, where applicable, as done for routine Doping Control (for example, for ERA or Homologous Blood transfusion (HBT) results, as established in the ISL TD EPO [7] and ISL TD HBT [8], respectively).WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 9/11

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 9/11 ISL TD2027EQAS – Version 1.0 – 01 January 2027 b) Laboratories shall report results for double-blind EQAS samples in ADAMS following the same procedure applied for the reporting of routine Doping Control test results (see ISL [1]). c) The deadline for reporting of double-blind EQAS results is twenty (20) days after receipt of the sample(s), unless:

1. GC/C/IRMS analysis has been requested as part of the initial Analytical Testing menu 5, or ii. The TA has been informed in writing of the need, with valid reason(s), for an extension of the reporting deadline. In the absence of feedback from the TA within seven (7) days of being notified, the Laboratory should assume that the extended reporting deadline has been accepted by the TA, or iii. A postponement has been established or approved by WADA based on justified grounds

(e.g. double-blind EQAS samples for which a second opinion may be required before reporting an Adverse Analytical Finding (AAF); the double-blind EQAS round coincides with national statutory holidays), or iv. The Laboratory is unable to perform the analysis and report results within twenty (20) days (or twenty five (25) days 5) of double-blind EQAS sample reception due to a temporary analytical incapacity ( e.g., instrument breakdown, need for method revalidation), in which case it should have informed the TA and WADA, if applicable (see ISL [1]). d) The double-blind EQAS round will be closed at the earliest of the two (2) following scenarios:

1. When all participating Laboratories have reported their doubleblind EQAS results in ADAMS, or

case it should have informed the TA and WADA, if applicable (see ISL [1]). d) The double-blind EQAS round will be closed at the earliest of the two (2) following scenarios:

1. When all participating Laboratories have reported their doubleblind EQAS results in ADAMS, or ii. Sixty (60) days from the date when the doubleblind EQAS sample(s) have been delivered to all participating Laboratories. e) For the evaluation of the late reporting of double-blind EQAS results, see ISL TD PERF [5]. 6.3 Reporting Educational EQAS Results The EQAS Participant shall report the results of open or blind educational EQAS samples on or before the specified reporting deadline and in a format specified by WADA in the educational EQAS Cover Letter. EQAS results received after the deadline may not be included in the assessment of EQAS results nor in the subsequent educational WADA EQAS Report.

The results from educational EQAS rounds may be used for data gathering to trigger Research & Development (R&D) activities, potentially leading to Test Method developments or improvements, as well as updates of ISL TDs and ISL TLs.

5 As per ISL [1], if GC/C/IRMS analysis has been requested as part of the initial Analytical Testing menu, the “A” Sample results should be reported in ADAMS within twenty-five (25) days of Sample receipt.WADA Technical Document – ISL TD2027EQAS Document number: ISL TD2027EQAS Version number: 1.0

Written by:

Reviewed by: WADA Science / TD EQAS Drafting Team

WADA Laboratory Expert Advisory Group Approved by: WADA Executive Committee Date: 02 December 2025 Effective date: 01 January 2027

Page 10/11 ISL TD2027EQAS – Version 1.0 – 01 January